Literature DB >> 27122230

A quantitative threshold for high/low extent of urinary excretion of compounds in humans.

Rutwij A Dave1, Marilyn E Morris1.   

Abstract

In this study, a quantitative threshold was determined for the high/low extent of urinary excretion (UE) of compounds in humans, using a straightforward but robust statistical method known as receiver operating characteristic curve (ROC) analysis, and also 18 potential physicochemical determinants of UE were evaluated. Data on the percent of drug excreted unchanged into the urine, %Ae , were used to determine the threshold for high/low UE. Compounds can be divided into high/low UE groups using the threshold value of Ae  = 16.8%, namely those with Ae  > 16.8% are classified as high UE and those with Ae  ≤ 16.8% as low UE. The %Ae negatively correlated with cLogP (r = -0.56); however, cLogP could not quantitatively predict the value of %Ae (R(2) adj. = 0.32). Several determinants of the extent of UE, including cLogP, ACD labs cLogP and ACD labs cLogD(pH=7.4) , were successfully evaluated as a priori indicators of the extent of UE using two cut-off values for each parameter. Moreover, 87% of the 90 compounds in the external validation set were correctly classified using this approach. Analysis of the physicochemical spaces of compounds in these two groups showed significant overlap, which hinders the a priori determination of the extent of UE of compounds using a single threshold/cut-off value of simple physicochemical parameters. In conclusion, 16.8% is a quantitative threshold value to distinguish between high and low UE and new molecular entities with cLogP and ACD labs cLogP values of ≤0.7 and ≥1.0 and ACD labs cLogD(pH=7.4) values of ≤0.0 and ≥0.5 could be identified as exhibiting high and low UE, respectively.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  ROC curve analysis; cLogD; cLogP; new molecular entities; urinary excretion

Mesh:

Substances:

Year:  2016        PMID: 27122230      PMCID: PMC4956512          DOI: 10.1002/bdd.2013

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  17 in total

Review 1.  Mechanisms and clinical implications of renal drug excretion.

Authors:  R Masereeuw; F G Russel
Journal:  Drug Metab Rev       Date:  2001 Aug-Nov       Impact factor: 4.518

Review 2.  Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system.

Authors:  Chi-Yuan Wu; Leslie Z Benet
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

3.  BDDCS applied to over 900 drugs.

Authors:  Leslie Z Benet; Fabio Broccatelli; Tudor I Oprea
Journal:  AAPS J       Date:  2011-08-05       Impact factor: 4.009

4.  The meaning and use of the area under a receiver operating characteristic (ROC) curve.

Authors:  J A Hanley; B J McNeil
Journal:  Radiology       Date:  1982-04       Impact factor: 11.105

Review 5.  The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development.

Authors:  Leslie Z Benet
Journal:  J Pharm Sci       Date:  2012-11-12       Impact factor: 3.534

6.  Quantitative structure-pharmacokinetic relationships for the prediction of renal clearance in humans.

Authors:  Rutwij A Dave; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2014-10-28       Impact factor: 3.922

7.  Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships.

Authors:  Xinning Yang; Yash A Gandhi; David B Duignan; Marilyn E Morris
Journal:  AAPS J       Date:  2009-07-11       Impact factor: 4.009

8.  A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability.

Authors:  G L Amidon; H Lennernäs; V P Shah; J R Crison
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

Review 9.  Prediction of human pharmacokinetics - renal metabolic and excretion clearance.

Authors:  Urban Fagerholm
Journal:  J Pharm Pharmacol       Date:  2007-11       Impact factor: 3.765

10.  Statistics review 13: receiver operating characteristic curves.

Authors:  Viv Bewick; Liz Cheek; Jonathan Ball
Journal:  Crit Care       Date:  2004-11-04       Impact factor: 9.097

View more
  1 in total

1.  In Vivo Targeting of Escherichia coli with Vancomycin-Arginine.

Authors:  Lewis F Neville; Itamar Shalit; Peter A Warn; Marc H Scheetz; Jiuzhi Sun; Madeline B Chosy; Paul A Wender; Lynette Cegelski; Jacob T Rendell
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.